Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Edward Arrowsmith
Phase II Study of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
British Journal of Haematology
Hematology
Related publications
Phase I/Ii Study of Carfilzomib, Bendamustine, and Dexamethasone (CBD) in Patients With Newly Diagnosed Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Phase II Trial to Investigate Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib
British Journal of Haematology
Hematology
Retreatment With Bendamustine-Bortezomib-Dexamethasone in a Patient With Relapsed/Refractory Multiple Myeloma
Case Reports in Hematology
Phase I/Ii Trial of Bendamustine, Ixazomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Single-Agent Thalidomide for Treatment of First Relapse Following High-Dose Chemotherapy in Patients With Multiple Myeloma
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Managing Neutropenia by Pegfilgrastim in Patients Affected by Relapsed/Refractory Multiple Myeloma Treated With Bendamustine-Bortezomib-Dexamethasone
Supportive Care in Cancer
Oncology
Bortezomib for the Treatment of Multiple Myeloma Patients
Health Technology Assessment
Medicine
Health Policy
Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib
Blood Cancer Journal
Oncology
Hematology
Chemotherapy Adherence Is a Favorable Prognostic Factor for Elderly Patients With Multiple Myeloma Who Are Treated With a Frontline Bortezomib-Containing Regimen
Yeungnam University Journal of Medicine
